The results of the 9th round of China’s national volume-based procurement (VBP) program have been announced, with a total of 175 drug manufacturers securing tender spots for 41 different drug products. The tender for levonorgestrel did not yield successful bids. Out of the 269 separate tender spots secured, only 5 foreign companies won 6 of those spots, with the majority of price reductions averaging 70% from the tender ceiling prices.<\/p>\n\n\n\n
Foreign Company Participation and Leading Bid Winners<\/strong>
Only one originator company, Ferring Pharmaceuticals with carbetocin, won a tender spot. The four successful foreign generic firms were all from India: Dr. Reddy’s with two bids, and Aurobindo, Cipla, and Hetero Labs. In terms of leading bid winners, CR Pharma topped the ranking with 8 bids, followed by Brilliant Pharma and Shanghai Pharma with 7 each. Qilu, Yangtze River Pharma, and Sino Biopharma each won 6, and Tianyao Pharma, Sinopharm, Chenpai Pharma, Cisen Pharma, SSY Group, China Meheco, and Kelun Pharma all had 4 successful bids each.<\/p>\n\n\n\n